Skip to main content
. 1999 Aug;73(8):6729–6742. doi: 10.1128/jvi.73.8.6729-6742.1999

TABLE 1.

Characteristics of Ad vectors

Trial Vector Lot no. PU/ml PFU/ml PU/PFUa Doses used for each administration (PU)
Normal skin AdGVCD.10 0061-0002 3.7 × 1011 1.0 × 1010 36 8 × 107–8 × 109
CF AdGVCFTR.10 0056-0002 2.2 × 1011 3.7 × 1010 6 3 × 107–3 × 108.5
 q3mo × 3 (part A)
  Individuals 1–8
AdGVCFTR.10 0045-007 1.4 × 1012 1.6 × 1011 9 3 × 109–3 × 1010
  Individuals 9–14
q15d × 4 (part B) AdGVCFTR.10 0045-007 1.4 × 1012 1.6 × 1011 9 3 × 109.5
Metastatic colon cancer AdGVCD.10 0061-0002 3.7 × 1011 1.0 × 1010 36 8 × 108–8 × 109
Coronary artery disease AdGVVEGF121.10 0061-0003 4.0 × 1011 1.0 × 1010 40 4 × 108–4 × 109.5
a

For convenience in discussing and graphing the data (Fig. 1 to 3), the ratios have been rounded off to the nearest 10 U, i.e., PU/PFU = 6 and 9 rounded to 10, and PU/PFU = 36 rounded to 40 (see Materials and Methods).